News for Sotera Health Company (SHC)

CLEVELAND, April 17, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solu

Sotera Health (SHC) will release its Q1 2025 earnings before market opens on May 1, 2025. A conference call is scheduled at 9:00 a.m. EDT to discuss the

**media[598564]**

Despite a 6% revenue decline in FY24 due to Nordion's lumpy revenue, Sotera Health maintains high adjusted EBITDA margins. Read why I'm bullish on SHC stock.

Sotera Health (SHC) stock drops as the company agrees to pay $30.9M to settle ethylene oxide claims tied to a former facility. Read more here.

For 2024, McIntyre Partnerships returned ~ 2% gross and 0% net vs. our benchmark, the Russell 2000 Value return of ~8%. Click here to read the full fund letter.

ROCKVILLE, Md., March 5, 2025 /PRNewswire/ -- Ascend Advanced Therapies (Ascend), a gene to GMP advanced therapy development partner, today announced the appointment of John Chiminski and Karen Flynn as non-executive members of its Board of Directors. John will serve as Chair of the Board and EW Healthcare Partners has designated Karen to serve on the Company's board as one of its representatives. Their leadership and deep industry expertise will be pivotal as Ascend builds its capabilities and positions itself for growth.

Rapid Sterility Testing yields product sterility test results in as little as 6 days and can be used for broadscale medical device and pharmaceutical product a

The following slide deck was published by Sotera Health Company in conjunction with their 2024 Q4 earnings call.

Sotera Health Company (NASDAQ:SHC) Q4 2024 Earnings Conference Call February 27, 2025 9:00 AM ETCompany ParticipantsJason Peterson – Vice President of...

Sotera Health Q4 results show 6.5% revenue decline to $290M; 2025 outlook projects steady growth with 4-6% revenue rise & EPS forecasted at $0.70-$0.76.

Although the revenue and EPS for Sotera Health (SHC) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Sotera Health (SHC) delivered earnings and revenue surprises of 0% and 0.46%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

2024 net revenues increased 4.9% to $1.10 billion, compared to 2023; or 5.4% on a constant currency basis2024 net income of $44 million or $0.16 per diluted sha

Evaluate the expected performance of Sotera Health (SHC) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

CLEVELAND, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company ( SHC), a leading global provider of mission-critical end-to-end sterilization solutions an

**media[543778]**

McIntyre Partnerships, an investment management company released its fourth quarter investor letter. McIntyre Partnerships returned approx.

We recently compiled a list of the Best Medical Stocks To Buy Under $20.